ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
ABBOTT LABORATORIES
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Jul 28, 2026
$104.06−0.83 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $181.80B
- P/E (TTM)
- 29.0
- Dividend yield
- 2.31%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
56.4%−0.2 pts over 5 years
Operating margin
18.2%+2.7 pts over 5 years
Net margin
14.7%+1.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.7% | +0.5% | +5.1% | +8.1% | |
| Gross profit | +7.6% | +0.7% | +5.0% | +7.9% | |
| Operating income | +18.0% | -1.2% | +8.5% | +10.9% | |
| Net income | -51.3% | -2.0% | +7.7% | +4.0% | |
| EPS, diluted | -51.3% | -1.6% | +8.3% | +2.5% | |
| Free cash flow | +16.4% | -1.8% | +5.3% | +14.8% | |
| Dividend per share | +7.1% | +7.7% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 6.7% | 14.1% | 13.1% | |
| Return on assets | 3.0% | 6.4% | 7.8% | |
| Current ratio | 4.02 | 1.72 | 1.58 | |
| Debt to equity | 1.07 | 0.57 | 0.25 | |
| Interest coverage | 7.0× | 9.8× | 16.3× | |
| Inventory turnover | 3.6× | 3.2× | 3.0× | |
| Capex to revenue | 5.4% | 6.3% | 4.9% | |
| Diluted shares | 1.48B | 1.79B | 1.75B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Abbott Laboratories generated $45.50B from operations and spent $37.77B on capital expenditure, dividends and share buybacks. 27% of that went back into the business.
Generated
$45.50B
Used
$37.77B
Capital expenditure$10.24B27%Dividends$18.02B48%Share buybacks$9.51B25%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin14.7%
×Asset turnover0.53×
×Equity multiplier1.68×
=Return on equity, FY202513.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 14.7% | 0.53× | 1.68× | 13.1% |
| FY2024 | 31.9% | 0.54× | 1.79× | 31.1% |
| FY2023 | 14.3% | 0.54× | 1.96× | 15.2% |
| FY2022 | 15.9% | 0.58× | 2.06× | 19.1% |
| FY2021 | 16.4% | 0.58× | 2.15× | 20.6% |
| FY2020 | 13.0% | 0.49× | 2.20× | 14.1% |
| FY2019 | 11.6% | 0.47× | 2.19× | 12.0% |
| FY2018 | 7.7% | 0.43× | 2.34× | 7.7% |
| FY2017 | 1.7% | 0.42× | 2.51× | 1.9% |
| FY2016 | 6.7% | 0.44× | 2.25× | 6.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$6.52B
- Cash generatingOperating cash flow above zero$9.57B
- Return on assets improvedROA up on the prior year18.3% → 8.0%
- Earnings backed by cashOperating cash flow above net income$9.57B vs $6.52B
- Less leverageLong-term debt to assets fell15.5% → 11.4%
- Better liquidityCurrent ratio rose1.67 → 1.58
- No dilutionShare count did not rise1.75B → 1.75B
- Gross margin improvedGross margin up on the prior year55.41% → 56.42%
- More efficientAsset turnover rose0.57 → 0.54